CG
VYGR icon

Cutler Group’s Voyager Therapeutics VYGR Stock Holding History

Cutler Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,600
Closed -$7K – 5314
2022
Q3 		$7K Sell
5,600
-2,000
-26% -$12.8K ﹤0.01% 3426
2022
Q2 		$12K Sell
7,600
-2,000
-21% -$13.5K ﹤0.01% 3082
2022
Q1 		$11K Buy
+9,600
New +$42.8K ﹤0.01% 3562
2018
Q2 		– Sell
-1,000
Closed -$1K – 4979
2018
Q1 		$1K Hold
1,000
– – ﹤0.01% 4196
2017
Q4 		$4K Buy
+1,000
New +$17.1K ﹤0.01% 3847

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cutler Group's VYGR Position: Q4 2022 in Review

Cutler Group sold out of Voyager Therapeutics (VYGR) in Q4 2022, closing a stake of 2,534 shares — an estimated $15K sold.

Cutler Group first reported a position in VYGR in Q3 2017 and held it in 7 quarters. The position peaked at $33K in Q2 2022. 70 funds tracked by Wall St. Rank hold VYGR as of Q4 2022.

  • Cutler Group reported no remaining Voyager Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 2,534 Voyager Therapeutics shares in Q4 2022, an estimated $15K.
  • Cutler Group first reported a position in Voyager Therapeutics in Q3 2017 and held it in 7 quarters.
  • Cutler Group's Voyager Therapeutics position peaked at $33K in Q2 2022.
  • 70 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.